Skip to Content

Insulin aspart / insulin degludec Side Effects

For the Consumer

Applies to insulin aspart / insulin degludec: subcutaneous solution

Along with its needed effects, insulin aspart/insulin degludec may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking insulin aspart/insulin degludec:

More Common

Less Common

  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • rapid weight gain
  • tingling of the hands or feet
  • unusual weight gain or loss

Incidence Not Known

  • Cough
  • decreased urine
  • difficulty with breathing or swallowing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • dry mouth
  • hives, itching, or skin rash
  • increased thirst
  • irregular heartbeat
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of appetite
  • muscle pain or cramps
  • numbness or tingling in the hands, feet, or lips
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • reddening of the skin, especially around the ears
  • sweating
  • tightness in the chest
  • vomiting

Some side effects of insulin aspart/insulin degludec may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Body aches or pain
  • ear congestion
  • fever
  • loss of voice
  • muscle aches
  • sneezing
  • stuffy or runny nose

Less Common

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site


  • Redistribution or accumulation of body fat

For Healthcare Professionals

Applies to insulin aspart / insulin degludec: subcutaneous solution


The most frequently reported adverse reactions include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain.[Ref]


Weight gain, attributed to the anabolic effects of insulin, has been reported. In clinical trials, an average weight gain of 1.6 kg and 2.8 kg was reported in patients with type 1 diabetes and type 2 diabetes, respectively.[Ref]

Very common (10% or more): Hypoglycemia (up to 95%)

Frequency not reported: Weight gain[Ref]


The incidence of insulin degludec-aspart anti-insulin antibodies has not been established. The detection of antibodies is dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. Therefore, comparison of the incidence of antibodies may be misleading. In a study in patients with type 1 diabetes, almost 96% of patients were positive for insulin degludec-aspart anti-insulin antibodies at least once during the studies, including almost 89% at baseline; while 13% were positive for insulin aspart anti-insulin antibodies at least once during the studies, including 6.4% at baseline.[Ref]

Common (1% to 10%): Influenza

Frequency not reported: Anti-insulin antibodies[Ref]


Common (1% to 10%): Peripheral edema[Ref]

In clinical trials, peripheral edema was reported in 2.2% and 1.8% of patients with type 1 diabetes and type 2 diabetes, respectively.[Ref]


Uncommon (0.1% to 1%): Hypersensitivity manifested with swelling of tongue and lips, diarrhea, nausea, tiredness and itching; urticaria[Ref]


Common (1% to 10%): Injection site reactions including hematoma, pain, hemorrhage, erythema, nodules, swelling, discoloration, pruritus, warmth, and injection site mass

Uncommon (0.1% to 1%): Lipodystrophy[Ref]


Very common (10% or more): Nasopharyngitis (up to 24.6%)

Common (1% to 10%): Upper respiratory tract infection[Ref]

Nervous system

Common (1% to 10%): Headache


1. "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.